$VTAE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Vitae Pharmaceuticals, Inc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Vitae Pharmaceuticals, Inc. Get notifications about new insider transactions in Vitae Pharmaceuticals, Inc for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Option Exercise | D | 8.78 | 16,500 | 144,870 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Option Exercise | D | 8.58 | 32,750 | 280,995 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Option Exercise | D | 8.28 | 21,250 | 175,950 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Option Exercise | D | 14.40 | 14,306 | 206,006 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Option Exercise | D | 7.13 | 21,647 | 154,343 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Sell | D | 21.00 | 228,274 | 4,793,754 | 228,274 | 456.5 K to 228.3 K (-50.00 %) |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Rowland Charles A Jr | Director | Option Exercise | D | 9.62 | 10,000 | 96,200 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Rowland Charles A Jr | Director | Option Exercise | D | 12.43 | 10,000 | 124,300 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Rowland Charles A Jr | Director | Option Exercise | D | 8.00 | 17,000 | 136,000 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | LEONARD JOHN M. | Director | Option Exercise | D | 9.62 | 10,000 | 96,200 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | LEONARD JOHN M. | Director | Option Exercise | D | 9.85 | 20,000 | 197,000 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Gunderson Robert V JR | Director | Option Exercise | D | 9.62 | 10,000 | 96,200 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Gunderson Robert V JR | Director | Option Exercise | D | 12.43 | 10,000 | 124,300 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Gunderson Robert V JR | Director | Option Exercise | D | 8.00 | 17,000 | 136,000 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Gunderson Robert V JR | Director | Option Exercise | D | 5.29 | 9,091 | 48,091 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Gunderson Robert V JR | Director | Option Exercise | D | 3.91 | 5,434 | 21,247 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Gunderson Robert V JR | Director | Sell | U | 21.00 | 15,830 | 332,430 | 0 | 15.8 K to 0 (-100.00 %) |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Gunderson Robert V JR | Director | Sell | U | 21.00 | 11,002 | 231,042 | 0 | 11 K to 0 (-100.00 %) |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Sable Carole | Chief Medical Offic ... | Option Exercise | D | 10.51 | 150,000 | 1,576,500 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 8.78 | 60,000 | 526,800 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 8.58 | 60,000 | 514,800 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 8.28 | 50,000 | 414,000 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 14.40 | 50,000 | 720,000 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 7.13 | 134,782 | 960,996 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 6.90 | 10,320 | 71,208 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 3.91 | 20,869 | 81,598 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 3.91 | 6,245 | 24,418 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 3.45 | 30,434 | 104,997 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 3.45 | 26,086 | 89,997 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Sell | U | 21.00 | 244,996 | 5,144,916 | 244,996 | 490 K to 245 K (-50.00 %) |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Option Exercise | D | 9.62 | 10,000 | 96,200 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Option Exercise | D | 12.43 | 10,000 | 124,300 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Option Exercise | D | 8.00 | 17,000 | 136,000 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Option Exercise | D | 5.29 | 18,182 | 96,183 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | JUNIUS DANIEL M | Director | Option Exercise | D | 11.37 | 20,000 | 227,400 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Bernstein Karen | Director | Option Exercise | D | 9.62 | 10,000 | 96,200 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Bernstein Karen | Director | Option Exercise | D | 11.01 | 20,000 | 220,200 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Fratamico Arthur | Chief Business Offi ... | Option Exercise | D | 8.78 | 14,500 | 127,310 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Fratamico Arthur | Chief Business Offi ... | Option Exercise | D | 8.58 | 19,250 | 165,165 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Fratamico Arthur | Chief Business Offi ... | Option Exercise | D | 8.28 | 13,750 | 113,850 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Fratamico Arthur | Chief Business Offi ... | Option Exercise | D | 14.40 | 13,750 | 198,000 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Fratamico Arthur | Chief Business Offi ... | Option Exercise | D | 5.29 | 152,173 | 804,995 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Fratamico Arthur | Chief Business Offi ... | Sell | U | 21.00 | 13,233 | 277,893 | 0 | 13.2 K to 0 (-100.00 %) |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | SANTINI GINO | Director | Option Exercise | D | 9.62 | 10,000 | 96,200 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | SANTINI GINO | Director | Option Exercise | D | 12.43 | 10,000 | 124,300 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | SANTINI GINO | Director | Option Exercise | D | 8.00 | 17,000 | 136,000 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Morris Richard Steven | Chief Financial Off ... | Option Exercise | D | 8.78 | 27,500 | 241,450 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Morris Richard Steven | Chief Financial Off ... | Option Exercise | D | 8.58 | 27,500 | 235,950 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Morris Richard Steven | Chief Financial Off ... | Option Exercise | D | 8.28 | 15,000 | 124,200 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Morris Richard Steven | Chief Financial Off ... | Option Exercise | D | 14.40 | 15,000 | 216,000 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Morris Richard Steven | Chief Financial Off ... | Option Exercise | D | 5.29 | 152,173 | 804,995 | 0 | |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Morris Richard Steven | Chief Financial Off ... | Sell | D | 21.00 | 828 | 17,388 | 0 | 828 to 0 (-100.00 %) |
Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Applebaum Scott | General Counsel | Option Exercise | D | 8.75 | 150,000 | 1,312,500 | 0 | |
Oct 21 2016 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Option Exercise | M | 14.40 | 6,944 | 99,994 | 14,306 | |
Oct 21 2016 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Option Exercise | M | 7.13 | 29,657 | 211,454 | 21,647 | |
Oct 21 2016 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Option Exercise | M | 3.91 | 87,301 | 341,347 | 0 | |
Oct 21 2016 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Buy | M | 14.40 | 6,944 | 99,994 | 228,274 | 221.3 K to 228.3 K (+3.14 %) |
Oct 21 2016 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Buy | M | 7.13 | 29,657 | 211,454 | 221,330 | 191.7 K to 221.3 K (+15.47 %) |
Oct 21 2016 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Buy | M | 3.91 | 87,301 | 341,347 | 191,673 | 104.4 K to 191.7 K (+83.64 %) |
Sep 16 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Sell | S | 20.81 | 50,000 | 1,040,500 | 244,996 | 295 K to 245 K (-16.95 %) |
Sep 16 2016 | VTAE | Vitae Pharmaceutic ... | ADAGE CAPITAL PARTNERS GP, L.L ... | 10% Owner | Sell | S | 20.85 | 1,025,000 | 21,371,250 | 2,375,000 | 3.4 M to 2.4 M (-30.15 %) |
Aug 17 2016 | VTAE | Vitae Pharmaceutic ... | Fratamico Arthur | Chief Business Offi ... | Option Exercise | A | 8.79 | 14,500 | 127,455 | 14,500 | |
Aug 17 2016 | VTAE | Vitae Pharmaceutic ... | Fratamico Arthur | Chief Business Offi ... | Grant | A | 6.11 | 2,086 | 12,745 | 12,086 | 10 K to 12.1 K (+20.86 %) |
Aug 17 2016 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Option Exercise | A | 8.79 | 16,500 | 145,035 | 16,500 | |
Aug 17 2016 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Grant | A | 6.11 | 2,100 | 12,831 | 104,372 | 102.3 K to 104.4 K (+2.05 %) |
Aug 17 2016 | VTAE | Vitae Pharmaceutic ... | Morris Richard Steven | Chief Financial Off ... | Option Exercise | A | 8.79 | 27,500 | 241,725 | 27,500 | |
Aug 17 2016 | VTAE | Vitae Pharmaceutic ... | Morris Richard Steven | Chief Financial Off ... | Grant | A | 6.11 | 828 | 5,059 | 828 | 0 to 828 |
Aug 17 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | A | 8.79 | 60,000 | 527,400 | 60,000 | |
Aug 17 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Grant | A | 6.11 | 747 | 4,564 | 294,996 | 294.2 K to 295 K (+0.25 %) |
Aug 12 2016 | VTAE | Vitae Pharmaceutic ... | Applebaum Scott | General Counsel | Option Exercise | A | 8.75 | 150,000 | 1,312,500 | 150,000 | |
Aug 12 2016 | VTAE | Vitae Pharmaceutic ... | Applebaum Scott | General Counsel | Option Exercise | A | 8.75 | 150,000 | 1,312,500 | 150,000 | |
Jul 27 2016 | VTAE | Vitae Pharmaceutic ... | JUNIUS DANIEL M | Director | Option Exercise | A | 11.37 | 20,000 | 227,400 | 20,000 | |
Jun 08 2016 | VTAE | Vitae Pharmaceutic ... | Sable Carole | Chief Medical Offic ... | Option Exercise | A | 10.51 | 150,000 | 1,576,500 | 150,000 | |
May 27 2016 | VTAE | Vitae Pharmaceutic ... | Gunderson Robert V JR | Director | Option Exercise | A | 9.62 | 10,000 | 96,200 | 10,000 | |
May 27 2016 | VTAE | Vitae Pharmaceutic ... | SANTINI GINO | Director | Option Exercise | A | 9.62 | 10,000 | 96,200 | 10,000 | |
May 27 2016 | VTAE | Vitae Pharmaceutic ... | Bernstein Karen | Director | Option Exercise | A | 9.62 | 10,000 | 96,200 | 10,000 | |
May 27 2016 | VTAE | Vitae Pharmaceutic ... | ROBERTS BRYAN E | Director | Option Exercise | A | 9.62 | 10,000 | 96,200 | 10,000 | |
May 27 2016 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Option Exercise | A | 9.62 | 10,000 | 96,200 | 10,000 | |
May 27 2016 | VTAE | Vitae Pharmaceutic ... | Rowland Charles A Jr | Director | Option Exercise | A | 9.62 | 10,000 | 96,200 | 10,000 | |
May 27 2016 | VTAE | Vitae Pharmaceutic ... | LEONARD JOHN M. | Director | Option Exercise | A | 9.62 | 10,000 | 96,200 | 10,000 | |
Mar 21 2016 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Option Exercise | M | 3.45 | 14,195 | 48,973 | 0 | |
Mar 21 2016 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Option Exercise | M | 3.45 | 1,935 | 6,676 | 0 | |
Mar 21 2016 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Sell | S | 7.42 | 16,130 | 119,685 | 0 | 16.1 K to 0 (-100.00 %) |
Mar 21 2016 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Buy | M | 3.45 | 14,195 | 48,973 | 14,195 | 0 to 14.2 K |
Mar 21 2016 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Buy | M | 3.45 | 1,935 | 6,676 | 1,935 | 0 to 1.9 K |
Feb 16 2016 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Scientific Of ... | Option Exercise | A | 8.58 | 32,750 | 280,995 | 32,750 | |
Feb 16 2016 | VTAE | Vitae Pharmaceutic ... | Morris Richard Steven | Chief Financial Off ... | Option Exercise | A | 8.58 | 27,500 | 235,950 | 27,500 | |
Feb 16 2016 | VTAE | Vitae Pharmaceutic ... | Fratamico Arthur | Chief Business Offi ... | Option Exercise | A | 8.58 | 19,250 | 165,165 | 19,250 | |
Feb 16 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | A | 8.58 | 60,000 | 514,800 | 60,000 | |
Dec 30 2015 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Option Exercise | M | 3.45 | 16,130 | 55,649 | 1,935 | |
Dec 30 2015 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Sell | S | 18.00 | 16,130 | 290,340 | 0 | 16.1 K to 0 (-100.00 %) |
Dec 30 2015 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Buy | M | 3.45 | 16,130 | 55,649 | 16,130 | 0 to 16.1 K |
Dec 28 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | M | 3.45 | 26,537 | 91,553 | 0 | |
Dec 28 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | M | 3.45 | 16,940 | 58,443 | 0 | |
Dec 28 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | M | 3.45 | 5,584 | 19,265 | 0 | |
Dec 28 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Buy | M | 3.45 | 26,537 | 91,553 | 293,897 | 267.4 K to 293.9 K (+9.93 %) |
Dec 28 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Sell | S | 17.00 | 22,524 | 382,908 | 267,360 | 289.9 K to 267.4 K (-7.77 %) |
Dec 28 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Buy | M | 3.45 | 16,940 | 58,443 | 289,884 | 272.9 K to 289.9 K (+6.21 %) |
Dec 28 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Buy | M | 3.45 | 5,584 | 19,265 | 272,944 | 267.4 K to 272.9 K (+2.09 %) |
Nov 17 2015 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Option Exercise | M | 3.91 | 15,000 | 58,650 | 87,301 | |
Nov 17 2015 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Option Exercise | M | 6.90 | 6,773 | 46,734 | 0 | |
Nov 17 2015 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Option Exercise | M | 3.91 | 13,695 | 53,547 | 0 | |
Nov 17 2015 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Option Exercise | M | 3.91 | 65,089 | 254,498 | 102,301 | |
Nov 17 2015 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Buy | M | 3.91 | 15,000 | 58,650 | 100,557 | 85.6 K to 100.6 K (+17.53 %) |
Nov 17 2015 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Buy | M | 6.90 | 6,773 | 46,734 | 85,557 | 78.8 K to 85.6 K (+8.60 %) |
Nov 17 2015 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Buy | M | 3.91 | 13,695 | 53,547 | 78,784 | 65.1 K to 78.8 K (+21.04 %) |
Nov 17 2015 | VTAE | Vitae Pharmaceutic ... | Gregg Richard | Chief Science Offic ... | Buy | M | 3.91 | 65,089 | 254,498 | 65,089 | 0 to 65.1 K |
Sep 30 2015 | VTAE | Vitae Pharmaceutic ... | Bernstein Karen | Director | Option Exercise | A | 11.01 | 20,000 | 220,200 | 20,000 | |
Sep 22 2015 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Option Exercise | M | 3.45 | 16,130 | 55,649 | 18,065 | |
Sep 22 2015 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Sell | S | 17.00 | 16,130 | 274,210 | 0 | 16.1 K to 0 (-100.00 %) |
Sep 22 2015 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Buy | M | 3.45 | 16,130 | 55,649 | 16,130 | 0 to 16.1 K |
Aug 31 2015 | VTAE | Vitae Pharmaceutic ... | Fratamico Arthur | Chief Business Offi ... | Buy | P | 7.83 | 10,000 | 78,266 | 10,000 | 0 to 10 K |
Jul 29 2015 | VTAE | Vitae Pharmaceutic ... | LEONARD JOHN M. | Director | Option Exercise | A | 9.85 | 20,000 | 197,000 | 20,000 | |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | NEWHALL CHARLES W III | Director | Buy | J | 0.00 | 289 | 0 | 289 | 0 to 289 |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | BARRETT M JAMES | 10% Owner | Buy | J | 0.00 | 464 | 0 | 464 | 0 to 464 |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | BARRETT M JAMES | 10% Owner | Buy | J | 0.00 | 1,134 | 0 | 1,134 | 0 to 1.1 K |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | BARRETT M JAMES | 10% Owner | Sell | I | 0.00 | 8,250 | 0 | 0 | 8.3 K to 0 (-100.00 %) |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | BARRETT M JAMES | 10% Owner | Buy | J | 0.00 | 8,250 | 0 | 8,250 | 0 to 8.3 K |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | BARRETT M JAMES | 10% Owner | Sell | J | 0.00 | 825,000 | 0 | 1,786,564 | 2.6 M to 1.8 M (-31.59 %) |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | SANDELL SCOTT D | 10% Owner | Buy | J | 0.00 | 556 | 0 | 556 | 0 to 556 |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | SANDELL SCOTT D | 10% Owner | Buy | J | 0.00 | 1,134 | 0 | 1,134 | 0 to 1.1 K |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | SANDELL SCOTT D | 10% Owner | Sell | J | 0.00 | 8,250 | 0 | 0 | 8.3 K to 0 (-100.00 %) |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | SANDELL SCOTT D | 10% Owner | Buy | J | 0.00 | 8,250 | 0 | 8,250 | 0 to 8.3 K |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | SANDELL SCOTT D | 10% Owner | Sell | J | 0.00 | 825,000 | 0 | 1,786,564 | 2.6 M to 1.8 M (-31.59 %) |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | BARRIS PETER J | 10% Owner | Buy | J | 0.00 | 1,171 | 0 | 1,171 | 0 to 1.2 K |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | BARRIS PETER J | 10% Owner | Buy | J | 0.00 | 97 | 0 | 97 | 0 to 97 |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | BARRIS PETER J | 10% Owner | Buy | J | 0.00 | 386 | 0 | 386 | 0 to 386 |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | BARRIS PETER J | 10% Owner | Buy | J | 0.00 | 1,134 | 0 | 1,134 | 0 to 1.1 K |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | BARRIS PETER J | 10% Owner | Sell | J | 0.00 | 8,250 | 0 | 0 | 8.3 K to 0 (-100.00 %) |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | BARRIS PETER J | 10% Owner | Buy | J | 0.00 | 8,250 | 0 | 8,250 | 0 to 8.3 K |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | BARRIS PETER J | 10% Owner | Sell | J | 0.00 | 825,000 | 0 | 1,786,564 | 2.6 M to 1.8 M (-31.59 %) |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | NEW ENTERPRISE ASSOCIATES 10 L ... | 10% Owner | Sell | J | 0.00 | 825,000 | 0 | 1,786,564 | 2.6 M to 1.8 M (-31.59 %) |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | NEA PARTNERS 10 L P | 10% Owner | Sell | J | 0.00 | 8,250 | 0 | 0 | 8.3 K to 0 (-100.00 %) |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | NEA PARTNERS 10 L P | 10% Owner | Buy | J | 0.00 | 8,250 | 0 | 8,250 | 0 to 8.3 K |
Jul 02 2015 | VTAE | Vitae Pharmaceutic ... | NEA PARTNERS 10 L P | 10% Owner | Sell | J | 0.00 | 825,000 | 0 | 1,786,564 | 2.6 M to 1.8 M (-31.59 %) |
Jun 01 2015 | VTAE | Vitae Pharmaceutic ... | ROBERTS BRYAN E | Director | Option Exercise | A | 12.43 | 10,000 | 124,300 | 10,000 | |
Jun 01 2015 | VTAE | Vitae Pharmaceutic ... | SANTINI GINO | Director | Option Exercise | A | 12.43 | 10,000 | 124,300 | 10,000 | |
Jun 01 2015 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Option Exercise | A | 12.43 | 10,000 | 124,300 | 10,000 | |
Jun 01 2015 | VTAE | Vitae Pharmaceutic ... | NEWHALL CHARLES W III | Director | Option Exercise | A | 12.43 | 10,000 | 124,300 | 10,000 | |
Jun 01 2015 | VTAE | Vitae Pharmaceutic ... | Gunderson Robert V JR | Director | Option Exercise | A | 12.43 | 10,000 | 124,300 | 10,000 | |
Jun 01 2015 | VTAE | Vitae Pharmaceutic ... | Rowland Charles A Jr | Director | Option Exercise | A | 12.43 | 10,000 | 124,300 | 10,000 | |
May 22 2015 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Option Exercise | M | 3.45 | 20,000 | 69,000 | 14,195 | |
May 22 2015 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Sell | S | 12.01 | 20,000 | 240,200 | 0 | 20 K to 0 (-100.00 %) |
May 22 2015 | VTAE | Vitae Pharmaceutic ... | HAYDEN DONALD J JR | Director | Buy | M | 3.45 | 20,000 | 69,000 | 20,000 | 0 to 20 K |
Mar 26 2015 | VTAE | Vitae Pharmaceutic ... | PROSPECT MANAGEMENT CO II LLC | 10% Owner | Buy | J | 0.00 | 20,357 | 0 | 28,237 | 7.9 K to 28.2 K (+258.34 %) |
Mar 26 2015 | VTAE | Vitae Pharmaceutic ... | PROSPECT MANAGEMENT CO II LLC | 10% Owner | Buy | J | 0.00 | 20,357 | 0 | 32,584 | 12.2 K to 32.6 K (+166.49 %) |
Mar 26 2015 | VTAE | Vitae Pharmaceutic ... | PROSPECT MANAGEMENT CO II LLC | 10% Owner | Sell | J | 0.00 | 900,383 | 0 | 1,672,140 | 2.6 M to 1.7 M (-35.00 %) |
Mar 17 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Payment of Exercise | F | 11.16 | 171,156 | 1,910,101 | 267,360 | 438.5 K to 267.4 K (-39.03 %) |
Mar 09 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | M | 1.15 | 8,115 | 9,332 | 0 | |
Mar 09 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Buy | M | 1.15 | 8,115 | 9,332 | 438,516 | 430.4 K to 438.5 K (+1.89 %) |